{"prompt": "['Apremilast', 'Protocol CC-10004-PSOR-020', 'Amgen Inc.', '6.4.11.', 'Patient Benefit Index (PBI)', 'The PBI is a validated patient-reported instrument to assess patient-relevant benefits', 'of psoriasis treatment (Feuerhahn, 2012). Prior to starting therapy, subjects are asked', 'to assess their treatment expectations by completing the Patient Needs Questionnaire', '(PNQ) (See Appendix K). After a period of treatment, subjects are then asked to', 'assess the benefits of treatment by completing the Patient Benefit Questionnaire', '(PBQ) (See Appendix L). The Patient Benefit Index represents the subject benefits', 'realized as a function of most important subject needs. The PBI score ranges from 0', '(no benefit) to 4 (maximum benefit).', '6.4.12.', 'The European Quality of Life 5-Dimension Questionnaire (EQ-5D)', \"EQ-5D (The EuroQol Group, 1990) measures the subject's general health state as a\", 'vertical VAS and 5 quality of life domains as multiple-choice questions: mobility,', 'self-care, main activity (work, study, housework, family/leisure activities),', 'pain/discomfort, and anxiety/depression, the combination of which generates 243', 'possible health states. See Appendix M.', '6.4.13.', 'The Work Productivity and Activity Impairment Questionnaire: Psoriasis', '(WPAI: PSO)', 'The WPAI: PSO questionnaire is a validated, 6-item self-administered instrument', 'used to assess the impact of disease on work productivity in psoriasis due to general', 'health or a specified health problem (Reilly, 2012; Appendix N).', '6.4.15.', 'Photography', 'Photographs will be collected only at selected sites, in subjects who consent, and will', 'be considered as supportive evidence of efficacy. Descriptive summary of', 'photography will be addressed in the statistical analysis plan (SAP) and included in', 'the clinical study report.', 'Confidential and Proprietary', '37', 'CC-10004-PSOR-020 Amendment 3 FINAL: 01 May 2020', 'EDMS Doc. Number: 24684941 - 22835610']['Apremilast', 'Protocol CC-10004-PSOR-020', 'Amgen Inc.', 'Photographs will be taken of all effected manifestations of plaque psoriasis at Weeks', '0, 16, 32, and 52. Appropriate protective mechanisms shall be implemented to ensure', 'that the photographs do not contain any subject-specific identifiers (such as tattoos,', 'scars, etc) when shared with the Sponsor.', 'The procedure for taking the photographs and processing and shipping photographs', 'will be described in a separate procedure manual distributed to investigational sites', 'performing photographic assessments.', 'Photographic assessments are an optional part of this study. Subjects enrolled at the', 'selected photography sites will be asked to sign a separate consent form specific to', 'photography at Visit 1 (Screening Visit), prior to being photographed.', '6.5.', 'Safety Assessments', 'In addition to safety monitoring conducted by Investigators and individual study personnel, AEs,', 'serious adverse events (SAEs), discontinuations and laboratory findings will be reviewed by the', 'study team. The review follows the Council for International Organizations for Medical', 'Sciences, Working Group VI (CIOMS VI) recommendations.', 'The study will be conducted in compliance with the ICH of Technical Requirements for', 'Registration of Pharmaceuticals for Human Use/GCP and applicable regulatory requirements.', 'The following assessments will be conducted as outlined in Table 3, Table of Events.', '6.5.1.', 'Serum and Urine Pregnancy Tests for Females of Childbearing Potential', 'A serum pregnancy test with a sensitivity of < 15 mIU/mL will be required for FCBP subjects at', 'Screening and the Week 52 Visit (or at the Early Termination Visit for subjects who prematurely', 'discontinue from the study). Urine pregnancy test will be performed on all FCBP subjects at the', 'Baseline Visit, prior to randomization. A urine pregnancy test kit will be provided by the central', 'laboratory. Pregnancy tests should be performed if the FCBP subject has missed a menstrual', 'period or the contraception method has changed.', '6.5.2.', 'Vital Signs, Weight and Waist Circumference', 'Vital signs, including pulse, and seated blood pressure, will be taken during the visits indicated', 'in Table 3, Table of Events. Weight and waist circumference will be measured and recorded at', 'the Screening Visit and then as indicated in Table 3, Table of Events; Body mass index (BMI)', 'will be calculated programmatically based on the Height measured and recorded at Screening. In', 'the event of unexplained and clinically significant weight loss, the patients should be evaluated', 'by the investigator and discontinuation of treatment should be considered (see Section 11).', '6.5.3.', 'Physical Examination', 'A physical examination includes evaluations of skin, nasal cavities, eyes, ears, lymph nodes, and', 'respiratory, cardiovascular, gastrointestinal, neurological, and musculoskeletal systems. A', 'physical examination is done at Screening as indicated in Table 3, Table of Events. Additional', 'physical examinations may be performed during the course of study as deemed necessary per', \"investigator's judgment and recorded in source documents.\", 'Confidential and Proprietary', '38', 'CC-10004-PSOR-020 Amendment 3 FINAL: 01 May 2020', 'EDMS Doc. Number: 24684941 - 22835610']['Apremilast', 'Protocol CC-10004-PSOR-020', 'Amgen Inc.', '6.5.4.', 'Psychiatric Evaluation', 'Treatment with apremilast is associated with an increase in adverse reactions of depression.', 'Before using apremilast in subjects with a history of depression and/or suicidal thoughts or', 'behavior, the Investigator should carefully weigh the risks and benefits of treatment with', 'apremilast in such patients. Subjects should be advised of the need to be alert for the emergence', 'or worsening of depression, suicidal thoughts or other mood changes, and if such changes occur', 'to contact the Investigator.', 'If a patient suffers from new or worsening psychiatric symptoms, or suicidal ideation is', 'identified, it is recommended to discontinue the subject participation to the study. Subjects who', 'are identified by the Investigator as having attempted suicide must be immediately withdrawn', 'from the study (see Section 11).', '6.5.5.', 'Severe Diarrhea, Nausea and Vomiting', 'There have been post-marketing reports of severe diarrhea, nausea, and vomiting associated with', 'the use of apremilast. Most events occurred within the first few weeks of treatment. In some', 'cases, patients were hospitalized. Patients 65 years of age or older and patients taking', 'medications that can lead to volume depletion or hypotension may be at a higher risk of', 'complications. Subjects should be monitored for severe diarrhea, nausea and vomiting. If', 'patients develop severe diarrhoea, nausea, or vomiting, discontinuation of treatment may be', 'necessary (see Section 11).', '6.5.6.', 'Clinical Laboratory Evaluations', 'Clinical laboratory evaluations will be performed as indicated in Table 3, Table of Events. These', 'include complete blood count (red blood cell [RBC] count, hemoglobin, hematocrit, white blood', 'cell [WBC] count and differential, absolute WBC counts, platelet count) and serum chemistries', 'including sodium, potassium, calcium, chloride, blood urea nitrogen (BUN), creatinine,', 'creatinine clearance, glucose, albumin, total protein, alkaline phosphatase, bilirubin (total and', 'direct), aspartate aminotransferase/serum glutamic oxaloacetic transaminase (AST/SGOT),', 'alanine aminotransferase/serum glutamic pyruvic transaminase (ALT/SGPT), gamma-glutamyl', 'transferase (GGT), lactate dehydrogenase (LDH). A lipid panel will be included in the standard', 'chemistry panel.', '6.5.7.', 'Tuberculosis', 'After an extensive clinical development program, there is no current evidence that apremilast has', 'the potential to activate latent TB. Therefore, no TB testing will be done in this protocol.', \"Investigators can test for TB if clinically indicated, using the site's local or country-specific\", 'guidelines. If the subject has active or latent TB, he/she should be treated according to local', 'guidelines. Subjects who require TB treatment at any time during the study must be', 'discontinued.', 'Confidential and Proprietary', '39', 'CC-10004-PSOR-020 Amendment 3 FINAL: 01 May 2020', 'EDMS Doc. Number: 24684941 - 22835610']", "completion": ""}